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Introduction: What are Nanoparticles?
 Nanoparticles are tiny (1-100 nm) particles that exhibit unique properties and 
characteristics at nano-scale.
 Many uses in the field of biomedicine and therapeutics
 Targeted drug delivery
 Encapsulation of small molecules (drugs, optical dyes)
 Dosage control and imaging
 Surface ligand modification (folic acid) for receptor specificity
 Only treat cells of interest
 MRI Contrast Imaging (Iron Oxide nanoparticles)
 Our Aim: Treat LNCaP strain prostate cancer with a combination therapy of soluble TNF-α
and LSLs with folate-functionalized iron oxide nanoparticles (IONPs)
Introduction: Why use TNF-α and LSLs?
 TNF-α
 Cytokine important in many cellular pathways
 Apoptosis and proliferation pathways
 In cancer cells, TNF-α and associated proteins behave aberrantly
 Nuclear factor kappa B (NF-κB) initiates proliferation unchecked
 Binding to its receptor, TNFR-1, does not occur in tumor cells
 Solution: Introduction of exogenous soluble TNF-α may help initiate cell death in 
tumors
 Inspired by Aurimune* (gold nanoparticle) 
 LSLs
 Glycolipids extracted from non-pathogenic yeast
 Enhance immune response and reduce inflammation
 Associated with large decreases in cytokine mRNA
 Suspected inhibition of NF-κB
 Implementation inspired by Dr. Richard Gross’ research
 Hypothesis: Synergy between these two compounds?
* Copyright © 2015 CytImmune Sciences, Inc.
Experimental: Nanoparticle Synthesis
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Results: IONP Characterization
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Results: Apoptosis/Necrosis Assay (TNF-α)
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Results: Apoptosis/Necrosis Assay Results
control TNF-alpha comb staurosp Inhibitor
0
10000
20000
30000
40000
50000
60000
F
lu
o
re
s
c
e
n
c
e
 u
n
it
Results: Migration Assay
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Conclusions
 Successful synthesis of folate-conjugated IONPs and 
encapsulation of TNF-α and LSLs
 Results of cytotoxicity assays show up to 80% cell death 
with combined treatment after 24 hrs
 Significant increase in apoptotic initiation following 24 hr. 
incubation with TNF-α and combination treatment
 Our results support our hypothesis the synergistic 
combined therapy
 Next step: Look to in-vivo mouse models for treatment
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